Top Section/Ad
Top Section/Ad
Most recent
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
Pair enjoyed strong execution and tight pricing as US high grade credit remained resilient in the face of a sell-off in equity markets
More articles/Ad
More articles/Ad
More articles
-
Valuation mismatch between issuer and investors prompted the decision to cancel the IPO -
Online pharmacy concludes the issue of convertible bonds, a delta placement and a tender offer
-
The first IPO in more than three years probably won’t reignite the Portuguese market
-
Like Renk and Douglas, Galderma has turned to the loan market over bonds after floating
-
The biggest IPO of 2024 so far in Europe has delivered a welcome bounce in the aftermarket
-
Galderma will provide the European IPO market with another important data point when it begins trading on Friday
